LOL So many incorrect shorts; Easily $100 a share if not more....
1) Not sure what you are on about. DCVax is approved in the NIH expensive drug list (you know the one over $30K). So that completely destroys your Pricing Pressure argument
2) Secondly, DCVax would not be paid out of an annual drug budget but rather from the Overall NHS Medicines Budget, so you are incorrect there as well.
3) AGAIN DCVAX IS APPROVED ON THE NIH EXPENSIVE DRUG LIST...
4) DCVax is multi-dosed, however this would still be included in the ~ $100K to $150K cost. And since 14,000 GBM patients are treated every year, it does not matter that there are multi doses, it is included in the overall costs ~>$100K per patient being treated.
5) Phase 1A of Cambridge Sawston provides production capacity of 450 - 500 patients per year, however Phase 1B which should bring the production up to 2,000 or more vaccines per year. Even just at ~$125K a patient, this would provide ~$70Million up to $250M and this does not include any US manufacturing, nor any manufacturing in Germany.
GBM alone would see 14,000 cases in the US, 14,000 cases in Europe. Even if DCVax-L was only 50% of those markets, they could command ~ 14,000 (7,000 US,+ 7,000 EU) which would provide $2B Revenue JUST FOR NEWLY DIAGNOSED GBM ALONE!!!
Lets take a similar company, like Seagen (SGEN). Has an annual revenue of $2B and has a market cap of ~$40B giving it a share price of $230/share. With a $40B market cap, that would give you a share price of ~$30 to $40/share (depending on the amount of shares outstanding ~ 1.2 B. AND THAT ONLY INCLUDES GBM patients. If you include ALL CANCER Patients, it would be well above $250 a share. Remember, stocks are about emotion, and what is the forward looking price. Once MHRA approval, well the sky is the limit. But thats for trying to make sense of all this... LOL
Bullish
Market Data 
Markets 
